Invention Application
- Patent Title: ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF
-
Application No.: US17570649Application Date: 2022-01-07
-
Publication No.: US20220220220A1Publication Date: 2022-07-14
- Inventor: Joseph M. Luettgen , Lumelle Schneeweis , Ginger Chao Rakestraw , Christina Terragni , Andrew Karl Dilger , Jason Robert Pinckney , Steven Sheriff , Kevin Kish , Yongmi An , William R. Ewing , Stanley Richard Krystek, JR. , Aaron Paul Yamniuk
- Applicant: Bristol-Myers Squibb Company , Janssen Pharmaceuticals, Inc.
- Applicant Address: US NJ Princeton; US NJ Titusville
- Assignee: Bristol-Myers Squibb Company,Janssen Pharmaceuticals, Inc.
- Current Assignee: Bristol-Myers Squibb Company,Janssen Pharmaceuticals, Inc.
- Current Assignee Address: US NJ Princeton; US NJ Titusville
- Main IPC: C07K16/36
- IPC: C07K16/36 ; C07K16/44 ; A61P7/04 ; G01N33/86 ; G01N33/94
Abstract:
The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
Public/Granted literature
- US12065505B2 Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof Public/Granted day:2024-08-20
Information query
